Table 1

Baseline characteristics

Early generation TAVI devicesNewer generation TAVI devicesP value
n=391n=391
Age (years)82.29±5.6782.67±6.350.377
Female gender, n(%)207 (52.9)208 (53.2)1.000
Body mass index (kg/m2)26.26±4.9426.45±5.230.614
Risk assessment
 STS score5.04±2.835.09±2.800.792
 Logistic EuroSCORE18.02±11.1518.08±13.230.945
Cardiac risk factors
 Diabetes mellitus, n (%)82 (21.0)108 (27.6)0.037
 Hypertension, n (%)323 (82.6)327 (83.6)0.775
 Dyslipidemia, n (%)233 (59.6)255 (65.2)0.121
Clinical features
 Renal failure (GFR <60 mL/min/1.73 m2)149 (38.3%)96 (24.7%)<0.001
 COPD, n (%)46 (11.8)35 (9.0)0.240
 Atrial fibrillation, n (%)134 (34.3)138 (35.3)0.822
 Permanent pacemaker, n (%)40 (10.2)43 (11.0)0.817
Past medical history
 Previous stroke or TIA, n (%)34 (8.7)44 (11.3)0.283
 Carotid artery disease, n (%)21 (5.5)29 (10.6)0.017
 Coronary artery disease, n (%)231 (59.1)249 (63.7)0.212
 Previous myocardial infarction, n (%)52 (13.3)55 (14.1)0.835
 Previous intervention, n (%)108 (27.6%)134 (34.3%)0.053
 CABG32 (8.5%)41 (10.5%)0.390
 PCI86 (22.0%)106 (27.2%)0.097
 Peripheral vascular disease, n (%)39 (10.0%)24 (6.1%)0.065
Echocardiographic findings
 Mean aortic valve area (cm2)0.65±0.230.68±0.270.106
 Mean aortic valve gradient (mm Hg)43.19±16.4841.45±19.070.199
 LVEF (%)55.50±14.2154.18±15.500.239
 Moderate/severe mitral regurgitation68 (18.9%)58 (15.6%)0.242
  • CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack.